LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
NCT01015118
Completed
The trial will be performed to evaluate if BIBF 1120 in combination with paclitaxel and carboplatin is more effective than placebo in combination with paclitaxel and carboplatin in first-line treatment of patients with advanced ovarian cancer. Safety information about BIBF1120/paclitaxel/carboplatin will be obtained.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/03/2017
Locations: 1199.15.10104 Boehringer Ingelheim Investigational Site, Austin, Texas +5 locations
Conditions: Ovarian Neoplasms, Peritoneal Neoplasms
Register for Updates
Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
NCT00335556
Completed
This phase II trial is studying how well combination chemotherapy, radiation therapy, and/or surgery work in treating patients with high-risk kidney tumors. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with radiat... Read More
Gender:
ALL
Ages:
29 years and below
Trial Updated:
06/22/2017
Locations: Texas Tech University Health Science Center-Amarillo, Amarillo, Texas +10 locations
Conditions: Childhood Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Clear Cell Sarcoma of the Kidney, Papillary Renal Cell Carcinoma, Rhabdoid Tumor of the Kidney, Stage I Renal Cell Cancer, Stage I Renal Wilms Tumor, Stage II Renal Cell Cancer, Stage II Renal Wilms Tumor, Stage III Renal Cell Cancer, Stage III Renal Wilms Tumor, Stage IV Renal Cell Cancer, Stage IV Renal Wilms Tumor
Register for Updates
Surgery in Treating Children With Neuroblastoma
NCT00003119
Completed
RATIONALE: Surgery alone may be effective in treating children with neuroblastoma. PURPOSE: Phase III trial to study the effectiveness of surgery alone in treating children who have neuroblastoma.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
03/09/2017
Locations: Texas Tech University Health Sciences Center School of Medicine, Amarillo, Texas +14 locations
Conditions: Neuroblastoma
Register for Updates
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
NCT01493505
Terminated
The purpose of this study is to determine whether AMG 386 or AMG 386 Placebo in combination with Paclitaxel and Carboplatin are effective in the treatment of ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/22/2017
Locations: Research Site, Austin, Texas +9 locations
Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Register for Updates
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
NCT01383148
Terminated
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC). TG4010 is a suspension of recombinant Modified Vaccinia virus strain Ankara (MVA strain) carrying coding sequences for human MUC1 antigen and human interleukin-2 (IL2). TG4010 has been developed for use as an immunotherapy in cancer patients whose tumors express the MUC1 antigen. TG401... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/04/2017
Locations: Texas Oncology, P.A. - Abilene (South), Abilene, Texas +1 locations
Conditions: Non-Small-Cell Lung Carcinoma
Register for Updates
Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00041054
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Exisulind may make tumor cells more sensitive to chemotherapy. Combining chemotherapy with exisulind may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining chemotherapy with exisulind in treating patients who have extensive-stage small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2016
Locations: Veterans Affairs Medical Center - Dallas, Dallas, Texas +1 locations
Conditions: Lung Cancer
Register for Updates
Ixabepilone + Carboplatin Metastatic Breast Cancer
NCT01075100
Completed
Ixabepilone adds significantly to the antitumor effectiveness of capecitabine in both ER+ and triple negative breast cancer. Ixabepilone has substantial antitumor activity in taxane-refractory patients and novel combinations are needed in this poor prognosis population. Carboplatin in combination with gemcitabine or paclitaxel has activity in metastatic breast cancer (MBC); there is also demonstrated activity of the gemcitabine/carboplatin combination in the ER+ versus triple negative subsets. A... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/14/2016
Locations: Texas Oncology - Abilene, Abilene, Texas +24 locations
Conditions: Metastatic Breast Cancer
Register for Updates
A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen
NCT01497470
Completed
The primary goal of this study is to determine if custirsen has an effect on the way the body distributes and gets rid of paclitaxel, the standard administered chemotherapy. The study will also evaluate if custirsen influences the way the body distributes and gets rid of carboplatin (another standard administered chemotherapy) and will measure custirsen blood levels in this cancer population. Finally, the study will evaluate the safety and tolerability of adding custirsen to the standard paclita... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2016
Locations: Teva Investigational Site 001, Dallas, Texas +1 locations
Conditions: Cancer
Register for Updates
Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer
NCT00874848
Completed
The Phase 2 study described in this protocol will serve to evaluate the antitumor activity, safety and pharmacokinetic profile of Imprime PGG when combined with cetuximab and concomitant paclitaxel and carboplatin therapy in patients with previously untreated advanced NSCLC. Additionally, this study will provide guidance for the design of more definitive efficacy studies of Imprime PGG in NSCLC patients.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/06/2016
Locations: Mary Crowley Medical Research Center, Dallas, Texas +1 locations
Conditions: NSCLC
Register for Updates
A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer
NCT01454089
Completed
The primary objective of this study is to ascertain whether there is evidence of longer survival relative to the control arm for three comparisons: 600 mg OGX-427 Arm to control Arm; 1000 mg OGX-427 Arm to control Arm; and pooled 600 mg and 1000 mg OGX-427 Arms to control Arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/06/2016
Locations: Texas Oncology, P.A., Dallas, Texas
Conditions: Urologic Neoplasms, Metastatic Bladder Cancer, Urinary Tract Neoplasms
Register for Updates
Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
NCT00303108
Completed
The purpose of this study is to determine the ORR associated with Doxil in combination with carboplatin in HER2- (negative) MBC (and with Herceptin in HER2+ MBC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/15/2016
Locations: Texas Cancer Center - Abilene (South), Abilene, Texas +26 locations
Conditions: Metastatic Breast Cancer
Register for Updates
A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
NCT00682981
Completed
The Phase I portion of this protocol will determine the best phase II dose and schedule of obatoclax with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. The Phase II portion will evaluate the response rate to this regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2016
Locations: Baylor, Dallas, Texas +2 locations
Conditions: Extensive-stage Small Cell Lung Cancer
Register for Updates